

- **Name:** Beodeul Kang
  - **Current Position & Affiliation:** Associate Professor, CHA Bundang Medical Center, CHA University
  - **Country:** Korea
- 

• **Educational Background:**

- |                 |   |
|-----------------|---|
| 2004.9 ~ 2009.2 | Yonsei University College of Medicine, Wonju, Korea   |
| 2011.3 ~ 2023.2 | Master's and Doctoral Joint Degree, Internal Medicine<br>Yonsei University College of Medicine, Seoul, Korea                              |
| 2009.3 ~ 2010.2 | Internship, Severance Hospital,<br>Yonsei University Health System, Seoul, Republic of Korea  |
| 2010.3 ~ 2014.2 | Residency in Internal Medicine, Severance Hospital,<br>Yonsei University Health System, Seoul, Republic of Korea                          |
| 2014.3 ~ 2015.2 | Fellowship in Medical Oncology, Yonsei Cancer Center,<br>Severance Hospital, Yonsei University Health System, Seoul,<br>Republic of Korea |

• **Professional Experience:**

- |                  |  |
|------------------|--|
| 2015.3 ~ 2018.2  | Palliative Care Attending physician<br>Division of hematology and medical oncology<br>Department of Internal Medicine<br>Seoul National University Bundang Hospital<br>Seongnam, Republic of Korea |
| 2018.2 ~ 2019.8  | Clinical Assistant Professor<br>Yonsei Cancer Center, Severance Hospital,<br>Yonsei University Health System, Seoul, Republic of Korea   |
| 2019.9 ~ 2021.2  | Clinical Assistant Professor<br>CHA Bundang Medical Center, CHA University<br>Seongnam, Republic of Korea  |
| 2021.3 ~ 2025.2  | Assistant Professor<br>CHA Bundang Medical Center, CHA University<br>Seongnam, Republic of Korea   |
| 2025.3 ~ present | Associate Professor<br>CHA Bundang Medical Center, CHA University<br>Seongnam, Republic of Korea   |

**• Professional Organizations:**

Member of American society of Oncology

Member of Korean Cancer Association

Member of Korean association of Internal Medicine

Member of Korean Association for Clinical Oncology

Member of Korean Society for Hospice and Palliative Care

**• Main Scientific Publications:**

1. Scheiner B, **Kang B**, et al. Outcome and management of patients with hepatocellular carcinoma who achieved a complete response to immunotherapy-based systemic therapy. *Hepatology*. 2024 Nov 21.
2. Hwang S, Woo S, **Kang B**, et al. Concordance of ctDNA and tissue genomic profiling in advanced biliary tract cancer. *J Hepatol*. 2024 Oct 21:S0168-8278(24)02641-2.
3. Kim YJ, Lee H, Woo HG, Lee SW, Hong M, Jung EH, Yoo SH, Lee J, Yon DK, **Kang B**. Machine learning-based model to predict delirium in patients with advanced cancer treated with palliative care: a multicenter, patient-based registry cohort. *Sci Rep*. 2024 May 20;14(1):11503.
4. Yoo SH, Kang J, Kim HJ, Lee SW, Hong M, Jung EH, Kim YJ, Yon DK, **Kang B**. Opioid use and subsequent delirium risk in patients with advanced cancer in palliative care: a multicenter registry study. *Sci Rep*. 2024 Mar 12;14(1):6004.
5. Jung EH, Yoo SH, Lee SW, **Kang B**, Kim YJ. Development of a Prediction Model for Delirium in Hospitalized Patients with Advanced Cancer. *Cancer Res Treat*. 2024 Oct;56(4):1277-1287. doi: 10.4143/crt.2023.1243. Epub 2024 Feb 26.
6. Cheon J, Kim H, Kim HS, Kim CG, Kim I, **Kang B**, Kim C, Jung S, Ha Y, Chon HJ. Atezolizumab plus bevacizumab in patients with child-Pugh B advanced hepatocellular carcinoma. *Ther Adv Med Oncol*. 2023 Jan 12;15.
7. Yang H, **Kang B**, Ha Y, Lee SH, Kim I, Kim H, Lee WS, Kim G, Jung S, Rha SY, Gaillard VE, Cheon J, Kim C, Chon HJ. High serum IL-6 correlates with reduced clinical benefit of atezolizumab and bevacizumab in unresectable hepatocellular carcinoma. *JHEP Rep*. 2023 Jan 16;5(4):100672.
8. Kim C, Yang H, Kim I, **Kang B**, Kim H, Kim H, Lee WS, Jung S, Lim HY, Cheon J, Chon HJ. Association of High Levels of Antidrug Antibodies Against Atezolizumab With Clinical Outcomes and T-Cell Responses in Patients with Hepatocellular Carcinoma. *JAMA Oncol*. 2022 Dec 1;8(12):1825-1829.